SCHEMBL5452931

SCHEMBL5452931

CCCCNc1cccc2c(-c3ccnc(OCC(F)(F)F)n3)c(-c3ccc(F)cc3)nn12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 5/20 0.49
GSK3B P49841 8/20 0.40
MAPK13 O15264 1/20 0.36
PRKD3 O94806 1/20 0.36
MAP4K4 O95819 1/20 0.36
FGFR1 P11362 1/20 0.36
MAPK1 P28482 1/20 0.36
KDR P35968 1/20 0.36
MAPK8 P45983 1/20 0.36
MAPK9 P45984 1/20 0.36
CSNK1A1 P48729 1/20 0.36
CSNK1D P48730 1/20 0.36
LIMK1 P53667 1/20 0.36
CSNK1G2 P78368 1/20 0.36
TAOK1 Q7L7X3 1/20 0.36
PRKD2 Q9BZL6 1/20 0.36
CSNK1G1 Q9HCP0 1/20 0.36
MAP4K5 Q9Y4K4 1/20 0.36
CSNK1G3 Q9Y6M4 1/20 0.36
AXL P30530 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14339988 0.91 MAPK14 (0.48) MAPK14GSK3BAXLTYRO3MERTK
SCHEMBL5457524 0.86 GSK3B (0.46) MAPK14GSK3BAXLTYRO3MERTK
SCHEMBL5455146 0.85 MAPK14 (0.43) MAPK14GSK3BAXLTYRO3MERTK
SCHEMBL5460142 0.84 GSK3B (0.45) MAPK14GSK3BAXLTYRO3MERTK
SCHEMBL5875632 0.84 MAPK14 (0.59) MAPK14GSK3BMAPK13PRKD3MAP4K4
SCHEMBL5460135 0.83 MAPK14 (0.41) MAPK14GSK3BMAPK13CSNK1DAXL
SCHEMBL5457545 0.83 MAPK14 (0.46) MAPK14MAPK13MAPK1MERTK
SCHEMBL5457474 0.82 GSK3B (0.49) MAPK14GSK3BMAPK13PRKD3MAP4K4
SCHEMBL5464066 0.82 GSK3B (0.43) MAPK14GSK3BAXLMERTK
SCHEMBL5452131 0.82 MAPK14 (0.40) MAPK14GSK3BAXLTYRO3MERTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1377573-B1 PYRAZOLOPYRIDINE DERIVATIVES GLAXO GROUP LTD (GB) 2005-07-27 EP claimed
US-20070287721-A1 Pyrazolopyridinyl pyridine BOYD F LESLIE 2007-12-13 US disclosed
US-7163940-B2 Pyrazolopyridinyl pyrimidine therapeutic compounds SMITHKLINE BEECHAM CORPORATION (US) 2007-01-16 US disclosed
US-7163940-B2 Pyrazolopyridinyl pyrimidine therapeutic compounds SMITHKLINE BEECHAM CORPORATION (US) 2007-01-16 US disclosed
EP-1377573-B1 PYRAZOLOPYRIDINE DERIVATIVES GLAXO GROUP LTD (GB) 2005-07-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287721-A1 Pyrazolopyridinyl pyridine CYP3A5, CYP2C19, CYP3A4 MAPK14 2533/4885GSK3B 2943/4885MAPK13 1668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.